One Rx
Two effective formulations

Convenient for patients who need treatment for both nonexcoriated scalp/skin and excoriated skin


Contents include:

  • OLUX® (clobetasol propionate) Foam with VERSAFOAM-HF® Vehicle, a hydroethanolic foam vehicle that delivers efficacy where needed

  • OLUX-E® (clobetasol propionate) Foam with VERSAFOAM-EF® Vehicle, an emulsion vehicle delivering efficacy with moisturizing properties

Available in 2 sizes:

  • OLUX® Foam 100 g and OLUX-E® Foam 10 g
    NDC# 00145-2300-03

  • OLUX® Foam 50 g and OLUX-E® Foam 10 g
    NDC# 00145-2200-03


Want to learn more? Click here to visit our WebExTM online seminar for more information on:


  • Managed care
  • Clinical summary
  • Ingredients
  • Patient preference information
  • FAQs

Directions for viewing the WebExTM

  1. When you get to the "Recording Information" screen, click the "Playback" button.
  2. The next page asks for some information about you—it is only necessary to fill in the asterisked (*) fields.
  3. A screen saying "Playback in Progress" will pop up.
  4. The WebExTM player will automatically download onto your computer.
  5. The WebExTM will start a few seconds after that—make sure your volume is turned up!
  6. To exit the WebExTM, simply click on the "X" box in the upper right hand corner.

FAQs


IMPORTANT SAFETY INFORMATION

OLUX® Foam is indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of non-scalp regions excluding the face and intertriginous areas. OLUX® Foam is not recommended for use in children under 12 years of age.

In clinical trials, the most common adverse events associated with the use of OLUX® Foam were burning, dryness, and other reactions at the application site.

OLUX-E® Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older.

The pooled incidence of local adverse reactions in trials for moderate to severe atopic dermatitis and mild to moderate plaque-type psoriasis with OLUX-E® Foam was 1.9% for application site atrophy and 1.6% for application site reaction.

Treatment with OLUX® Foam or OLUX-E® Foam beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

OLUX-E® Foam should be applied to the affected area twice daily.

Please see accompanying full Prescribing Information for OLUX® Foam and OLUX-E® Foam.

The Foam Dollop Design is a trademark, and STIEFEL, STIEFEL & Design, the V Design, OLUX, OLUX-E, OLUX-E & Design, VERSAFOAM, VERSAFOAM-HF, and VERSAFOAM-EF are registered trademarks of Stiefel Laboratories, Inc.

Rebate Offer

Instantly save up to $35 off your OLUX® Foam prescription (even works with copay).

learn more

Patient Information Brochure

Download this helpful patient information brochure to learn more about OLUX® Foam and scalp dermatoses.

download